Form 4: Vistagen Therapeutics Grants Stock Options to Chief Corporate Development Officer Elissa S. Cote

Vistagen Therapeutics, Inc. has granted 150,000 stock options to its Chief Corporate Development Officer, Elissa S. Cote, as part of her compensation package.

Summary

• Elissa S. Cote, Chief Corporate Development Officer of Vistagen Therapeutics, Inc. (VTGN), was granted 150,000 stock options.
• The options have an exercise price of $1.96 per share.
• The grant date for these options was June 23, 2025.
• The options will vest over a period, with 25% vesting on June 23, 2026 (the 'Vesting Start Date').
• Following the initial vesting, 1/36th of the remaining shares will vest monthly until fully vested three years after the Vesting Start Date.
• The stock options are set to expire on June 23, 2035.
• This grant is in connection with Ms. Cote's appointment as Chief Corporate Development Officer.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. This is a standard executive compensation event, aligning management interests with shareholders, which is generally viewed favorably. It does not indicate any immediate financial performance or strategic shifts.

Positives

• The grant of stock options to a key executive like the Chief Corporate Development Officer helps align her interests with those of the shareholders, incentivizing long-term company performance.
• This is a standard practice for executive compensation, indicating a structured approach to attracting and retaining talent.

Future Outlook

The vesting schedule for the stock options, extending over three years post-Vesting Start Date, indicates a long-term commitment and incentive structure for the Chief Corporate Development Officer.

Management Comments

• The stock options were granted in connection with the Reporting Person's appointment as Chief Corporate Development Officer.

Industry Context

The granting of stock options is a common and standard practice in the biotechnology and pharmaceutical industries for executive compensation, aiming to attract, retain, and incentivize key talent by aligning their financial interests with the company's long-term performance and shareholder value creation.

Comparison to Industry Standards

• The granting of stock options as part of executive compensation is a standard practice across the biotechnology and pharmaceutical sectors, similar to compensation structures observed at companies like Moderna, Pfizer, or Amgen for their senior executives.
• While the specific number of options (150,000) and exercise price ($1.96) are unique to this grant, the general mechanism of performance-based vesting over several years is consistent with industry benchmarks designed to foster long-term commitment and performance.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of stock options aims to align the interests of the Chief Corporate Development Officer with shareholders, potentially leading to improved long-term company performance and value creation.
• Employees: Standard executive compensation practices can signal stability and a structured approach to talent management within the company.

Next Steps

• The vesting of the stock options will commence on June 23, 2026, with subsequent monthly vesting over the following three years.

Key Dates

Keywords

Vistagen Therapeutics, VTGN, Stock Options, Executive Compensation, SEC Form 4, Insider Transaction, Chief Corporate Development Officer, Equity Grant, Biotechnology, Pharmaceuticals